Overall Fundamental outlook

Business Operations:

Sector: Healthcare
Industry: Drug Manufacturers - Specialty & Generic

Mankind Pharma Limited develops, manufactures, and markets pharmaceutical formulations and consumer healthcare products primarily in India and internationally. The company develops pharmaceuticals for acute and chronic therapeutics in the areas of anti-infective, cardiovascular, gastrointestinal, anti-diabetic, dermatology, pain/analgesics, neuro/CNS, vitamins/minerals/nutrients, and respiratory diseases. It provides consumer healthcare products, such as condoms, pregnancy detection kits, emergency contraceptives, antacid powders, vitamin and mineral supplements, and anti-acne preparations. The company offers its products primarily under the Manforce, Prega News, Unwanted-72, Gas-O-Fas, Health OK, and AcneStar brand names. In addition, it engages in the trading and exporting of pharmaceutical and health care products; manufacturing of packing materials ayurvedic products, packing materials, bulk drugs, and consumer goods; real estate, leasing, and hospitality businesses; and provision of IT services. The company was incorporated in 1991 and is based in New Delhi, India.

Revenue projections:

Revenue projections for MANKIND
Revenue projections for MANKIND

The projected decline in MANKIND's revenues compared to last year is expected to make investors cautious. A drop in revenue often has a direct negative effect on the company's bottom line, signaling potential challenges that could undermine investor confidence and reduce overall profitability.

Financial Ratios:

currentRatio 1.06900
forwardPE 34.33583
debtToEquity 38.11100
earningsGrowth 0.31700
revenueGrowth 0.11800
grossMargins 0.71619
operatingMargins 0.20558
trailingEps 46.29000
forwardEps 71.70352

Mankind Pharma Limited's current ratio, being 1.069, means the company is well-positioned to meet its short-term debt obligations. This reflects Mankind Pharma Limited's strong liquidity, as its cash reserves and current assets provide more than enough coverage for its immediate liabilities.
With positive growth in both earnings and revenue, MANKIND is expected to grow its business. These indicators highlight a strong financial outlook, with the company on track for continued expansion and increasing profitability.
Mankind Pharma Limited's positive gross and operating margins indicate that the company is performing profitably. These margins reflect efficient cost control and revenue generation, signaling a strong financial foundation for continued success.
With MANKIND's forward EPS higher than its trailing EPS, the company is expected to be more profitable in the current financial year. This signals confidence in MANKIND's growth potential, as improved earnings are forecasted compared to the prior year's performance.

Price projections:

Price projections for MANKIND
Price projections for MANKIND

Price projections for MANKIND have gradually risen over time, signaling increased optimism about the company's future prospects. This steady upward revision reflects growing confidence in MANKIND's market potential.

Recommendation changes over time:

Recommendations trend for MANKIND
Recommendations trend for MANKIND


Analysts have shown a buy bias for Mankind Pharma Limited, marking it as a favorable investment option. This could inspire investors to see Mankind Pharma Limited as a strong place to park their money, given the positive outlook and growth potential associated with the stock in recent evaluations.